Literature DB >> 16514635

Expression of mutant cartilage oligomeric matrix protein in human chondrocytes induces the pseudoachondroplasia phenotype.

Thomas M Merritt1, Joseph L Alcorn, Richard Haynes, Jacqueline T Hecht.   

Abstract

Over 70 mutations in the cartilage oligomeric matrix protein (COMP), a large extracellular pentameric glycoprotein synthesized by chondrocytes, have been identified as causing two skeletal dysplasias: multiple epiphyseal dysplasia (MED/EDM1), and a dwarfing condition, pseudoachondroplasia (PSACH). These mutations induce misfolding of intracellular COMP, resulting in retention of the protein in the rough endoplasmic reticulum (rER) of chondrocytes. This accumulation of COMP in the rER creates the phenotypic enlarged rER cisternae in the cells, which is believed to compromise chondrocyte function and eventually cause cell death. To study the molecular mechanisms involved with the disease, we sought to develop an in vitro model that recapitulates the PSACH phenotype. Normal human chondrocytes were transfected with wildtype (wt-) COMP or with mutant COMP (D469del; mt-) recombinant adenoviruses and grown in a nonattachment redifferentiating culture system that provides an environment allowing formation of a differentiated chondrocyte nodule. Visualization of normal cells expressing COMP suggested the hallmarks of the PSACH phenotype. Mutant COMP expressed in normal cells was retained in enlarged rER cisternae, which also retained IX collagen (COL9) and matrilin-3 (MATN3). Although these proteins were secreted normally into the ECM of the wt-COMP nodules, reduced secretion of these proteins was observed in nodules composed of cells transfected with mt-COMP. The findings complement those found in chondrocytes from PSACH patient growth plates. This new model system allows for production of PSACH chondrocyte pathology in normal costochondral chondrocytes and can be used for future mechanistic and potential gene therapy studies. Copyright 2006 Orthopaedic Research Society

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16514635     DOI: 10.1002/jor.20100

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  16 in total

1.  Mutant cartilage oligomeric matrix protein (COMP) compromises bone integrity, joint function and the balance between adipogenesis and osteogenesis.

Authors:  Francoise Coustry; Karen L Posey; Tristan Maerz; Kevin Baker; Annie M Abraham; Catherine G Ambrose; Sabah Nobakhti; Sandra J Shefelbine; Xiaohong Bi; Michael Newton; Karissa Gawronski; Lindsay Remer; Alka C Veerisetty; Mohammad G Hossain; Frankie Chiu; Jacqueline T Hecht
Journal:  Matrix Biol       Date:  2018-01-05       Impact factor: 11.583

Review 2.  Novel therapeutic interventions for pseudoachondroplasia.

Authors:  Karen L Posey; Jacqueline T Hecht
Journal:  Bone       Date:  2017-03-21       Impact factor: 4.398

3.  Novel mTORC1 Mechanism Suggests Therapeutic Targets for COMPopathies.

Authors:  Karen L Posey; Francoise Coustry; Alka C Veerisetty; Mohammad G Hossain; Michael J Gambello; Jacqueline T Hecht
Journal:  Am J Pathol       Date:  2019-01       Impact factor: 4.307

4.  Chop (Ddit3) is essential for D469del-COMP retention and cell death in chondrocytes in an inducible transgenic mouse model of pseudoachondroplasia.

Authors:  Karen L Posey; Francoise Coustry; Alka C Veerisetty; Peiman Liu; Joseph L Alcorn; Jacqueline T Hecht
Journal:  Am J Pathol       Date:  2011-12-07       Impact factor: 4.307

5.  D469del-COMP retention in chondrocytes stimulates caspase-independent necroptosis.

Authors:  Françoise Coustry; Karen L Posey; Peiman Liu; Joseph L Alcorn; Jacqueline T Hecht
Journal:  Am J Pathol       Date:  2011-12-07       Impact factor: 4.307

6.  Antisense Reduction of Mutant COMP Reduces Growth Plate Chondrocyte Pathology.

Authors:  Karen L Posey; Francoise Coustry; Alka C Veerisetty; Mohammad Hossain; Danielle Gattis; Sheri Booten; Joseph L Alcorn; Punit P Seth; Jacqueline T Hecht
Journal:  Mol Ther       Date:  2017-02-03       Impact factor: 11.454

7.  Ribozyme-mediated reduction of wild-type and mutant cartilage oligomeric matrix protein (COMP) mRNA and protein.

Authors:  Joseph L Alcorn; Thomas M Merritt; Mary C Farach-Carson; Huiqui H Wang; Jacqueline T Hecht
Journal:  RNA       Date:  2009-02-23       Impact factor: 4.942

8.  RNAi reduces expression and intracellular retention of mutant cartilage oligomeric matrix protein.

Authors:  Karen L Posey; Peiman Liu; Huiqiu R Wang; Alka C Veerisetty; Joseph L Alcorn; Jacqueline T Hecht
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

9.  An inducible cartilage oligomeric matrix protein mouse model recapitulates human pseudoachondroplasia phenotype.

Authors:  Karen L Posey; Alka C Veerisetty; Pieman Liu; Huiqiu R Wang; Brian J Poindexter; Roger Bick; Joseph L Alcorn; Jacqueline T Hecht
Journal:  Am J Pathol       Date:  2009-09-17       Impact factor: 4.307

10.  Mutations targeting intermodular interfaces or calcium binding destabilize the thrombospondin-2 signature domain.

Authors:  C Britt Carlson; Kristin A Gunderson; Deane F Mosher
Journal:  J Biol Chem       Date:  2008-08-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.